TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04239833
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).
Study: NCT02776189
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
Study: NCT02776189
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
Study: NCT04239833
Drug: Placebo Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT00018733
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01650350
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study.
Study: NCT02711852
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as oral capsules
Study: NCT04899271
Drug: Ladarixin
Normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg b.i.d. for 13 cycles of 14 days on/14 days off
Study: NCT00455689
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women.
Study: NCT01298752
Drug: Mapracorat
Normalized name: Mapracorat
DrugBank: Mapracorat (DB12041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
Study: NCT03552393
Drug: Mircera
Normalized name: Mircera
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
Study: NCT02414152
Drug: anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
Study: NCT04191187
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2
Study: NCT04191187
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
Study: NCT00359281
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
Study: NCT00359281
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10 mg and AEGR-733 10 mg
Study: NCT00359281
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized Fenofibrate 145 mg and AEGR-733 10 mg
Study: NCT00359281
Drug: dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 30 mg and AEGR-733 10 mg
Study: NCT00359281
Drug: Extended Release Niacin
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ER niacin and AEGR-733 10 mg
Study: NCT00448903
Drug: Bemiparin
Normalized name: Bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bemiparin sodium
Study: NCT01891500
Drug: Nitrogen Gas
Normalized name: nitrogen Gas for Inhalation
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
Study: NCT01891500
Drug: Crossover iNO
Normalized name: INO
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
Study: NCT00864643
Drug: Lapaquistat acetate and atorvastatin
Normalized name: atorvastatin and amlodipine
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
Study: NCT00864643
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
Study: NCT03491579
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
Study: NCT03491579
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard chemotherapy
Study: NCT03491579
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy
Study: NCT01557712
Drug: ketamine venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of ketamine~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder
Study: NCT01557712
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder
Study: NCT02100761
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
Study: NCT01619982
Drug: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.
Study: NCT01846611
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
Study: NCT01846611
Drug: DOXIL
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
Study: NCT00280553
Drug: bupivicaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA and bupivicaine infusion for up to five days
Study: NCT02144753
Drug: psyllium (15 g)
Normalized name: psyllium
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
Study: NCT01945164
Drug: XL999
Normalized name: XL999
DrugBank: XL999 (DB05014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
Study: NCT03233724
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
Study: NCT03233724
Drug: Tetrahydrouridine (THU)
Normalized name: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
Study: NCT03233724
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
Study: NCT03373162
Drug: onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
Study: NCT00545064
Drug: dorzolamide hydrochloride (+) timolol maleate
Normalized name: dorzolamide / timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
Study: NCT02534688
Drug: DMPA
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03122457
Drug: lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
Study: NCT04302662
Drug: MS1819-SD
Normalized name: MS1819-SD
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.
Study: NCT01327222
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg intravitreal bevacizumab
Study: NCT00047060
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine
Study: NCT00047060
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine
Study: NCT00047060
Drug: Campath
Normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Campath
Study: NCT02238873
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01114893
Drug: Travoprost 0.004%
Normalized name: TRAVOPROST 0.004% SOLN,OPH
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
Study: NCT01114893
Drug: Travoprost Vehicle
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop in each eye 8 times daily for 5 days
Study: NCT01114893
Drug: Travoprost (Groups A, B and C)
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop in each eye 8 times daily for 5 days
Study: NCT00950989
Drug: Brodalumab
Normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
Study: NCT03123471
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30 mg tablets BID from weeks 0 to 32.
Study: NCT02189213
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline will be administered to treat anxiety disorders in children and adolescents.
Study: NCT04457050
Drug: Sofosbuvir 400 milligram
Normalized name: Product containing precisely sofosbuvir 400 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single daily dose of 400 milligrams
Study: NCT04457050
Drug: Daclatasvir 60 milligram
Normalized name: daclatasvir 60 MG
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single daily dose of 60 milligrams for 12 weeks
Study: NCT04457050
Drug: Ribavirin 400 milligram
Normalized name: Product containing precisely ribavirin 400 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks
Study: NCT04457050
Drug: Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single daily dose for 12 weeks
Study: NCT02016820
Drug: Omeprazole (suspension)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg/day
Study: NCT00091104
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04688775
Drug: Eptinezumab
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab - concentrate for solution for infusion, intravenously
Study: NCT03786562
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1
Study: NCT03786562
Drug: Intrathecal Morphine + Intravenous Nalbuphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2
Study: NCT01303042
Drug: Insulin lispro mix 50/50
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 50/50 t.i.d : six months
Study: NCT00455013
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
Study: NCT00455013
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
Study: NCT00455013
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
Study: NCT00455013
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
Study: NCT00455013
Drug: Mycophenolate Mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
Study: NCT01249651
Drug: esomeprazole 40 mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole 40 mg once daily, 8 weeks
Study: NCT01619982
Drug: Cefazolin 30 mg/kg body weight
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery.
Study: NCT02873936
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT02873936
Drug: Placebo to match filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT02047253
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
Study: NCT02047253
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered prior to administration of Study drug
Study: NCT02047253
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally twice daily
Study: NCT01548248
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
Study: NCT01548248
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
Study: NCT01108094
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months
Study: NCT00705536
Drug: Humalog
Normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02697864
Drug: tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00705536
Drug: Humulin-R
Normalized name: INSULIN REG HUMULIN-R 100 U/ML CARTRIDGE,1.5ML
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00705536
Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Normalized name: PEGylated recombinant human hyaluronidase PH20
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no